Market Events and Forecast | Ophthalmology | US/EU5 | 2021

In 2019, sales of branded biologics in ophthalmology reached almost $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, reference brands Lucentis (ranibizumab) and Eylea (aflibercept) are set to lose patent protection; biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these two key reference brands and their biosimilars by molecule and region.

Login to access report

launch Related Market Assessment Reports